



RECEIVED
FEB 11 2003
TECH CENTER 1600/2900

Client Ref.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Applicant: FANG, Fang

Appl. No.: 09/910,483

Filing Date: July 19, 2001

Examiner: Wortman, D.

Group Art Unit: 1648

Date: February, 2003

Page

1

of

2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	5,223,396	06/1993	Rothlein			05/03/1991
BR	5,324,510	06/1994	Wegner			03/18/1993
CR	5,475,091	12/1995	Springer			01/25/1994
DR	5,530,101	06/1996	Queen			12/19/1990
ER	5,565,550	10/1996	Springer			02/10/1994
FR	5,731,168	03/1998	Carter			03/01/1995
GR	5,821,123	10/1998	Studnicka			06/07/1995
HR	5,821,337	10/1998	Carter			08/21/1992
IR	5,910,573	06/1999	Plückthun			01/15/1993
JR	6,129,914	10/2000	Weiner			03/01/1995
KR	6,329,511	12/2001	Vasquez			11/29/1999
LR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Encl osed	No	Encl ose	No
MR	WO 88/01649	03/1988	PCT	Ladner	Y			
NR	WO 90/07861	07/1990	PCT	Queen	Y			
OR	WO 91/07418	05/1991	PCT	Better	Y			
PR	WO 91/07493	05/1991	PCT	Better	Y			
QR	WO 91/07494	05/1991	PCT	Better	Y			
RR	WO 91/16927	11/1991	PCT	Adair	Y			
SR	WO 91/16928	11/1991	PCT	Adair	Y			
TR	WO 92/11018	07/1992	PCT	Queen	Y			
UR	WO 92/22653	12/1992	PCT	Carter	Y			
VR	WO 93/06213	04/1993	PCT	Hoogenboom	Y			
WR	WO 93/11794	06/1993	PCT	Studnicka	Y			
XR	WO 93/23434	11/1993	PCT	Theofan	Y			
YR	WO 94/04679	03/1994	PCT	Carter	Y			
ZR	WO 95/27736	10/1995	PCT	Wegner	Y			
AAR	WO 9634015	10/1996	PCT	Faanes	Y			
BBR	EP 0169146 A2	01/1986	EP	Colonno	Y			
CCR	EP 0239400 A2	09/1987	EP	Winter	Y			

Handwritten signature and date: 4/28/03

DDP	DDR	EP 0239400 B1	09/1987	EP	Winter		Y			
FFR	EPR	EP 0387701 A1	09/1990	EP	Wegner		Y			
FFR	FFR	EP 0387701 B1	09/1990	EP	Wegner		Y			
FFR	FFR	EP 0404003 A2	12/1990	EP	Better		Y			
HHR	HHR	EP 0451216 B1	10/1991	EP	Queen		Y			
HHR	HHR	EP 0459577 A2	12/1991	EP	Colonio		Y			
JJR	JJR	EP 0528931 B1	03/1993	EP	Adair		Y			
KKR	KKR	EP 0605522 B1	07/1994	EP	Hoogenboom		Y			
LLR	LLR	EP 0682040 A1	11/1995	EP	Queen		Y			
MMR	MMR	EP 0682040 B1	11/1995	EP	Queen		Y			
NNR	NNR	EP 0939127 A2	09/1999	EP	Queen		Y			
OOR	OOR	EP 0967277 A2	12/1999	EP	Better		Y			
	PPR	JP 10-101699								
	QQR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)										
	RRR						Y			
	SSR						Y			
	TTR						Y			
	UUR						Y			
	VVR						Y			
	WWR						Y			
	XXR						Y			

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



To:

Atty.
Dkt. No.

M#

Client R f.

0278772

014357

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: FANG, Fang

Appln. No.: 09/910,483

Filing Date: July 19, 2001

Date: Oct ber 10, 2003

Page

1

of 1

Examiner: Wortman, D.

Group Art Unit: 1648

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						

RECEIVED
OCT 22 2003

TECH CENTER 1032

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Encl osed	No	Encl ose	No
<i>de</i>	FR	WO 91/16927	11/1991	PCT	Adair	Y			
	GR								
	HR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

<i>de</i>	IR	Foot, et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <i>J. mol. Biol.</i> (1992) Vol. 224, pp. 487-490.	Y		
<i>ell</i>	JR	PCT International Search Report, dated September 8, 2003 for PCT/US 02/23002	Y		

Examiner *Charles H*

Date Considered: 5/20/04

*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
OCT 22 2003
TECH CENTER 1032



FORM PTO-1449 (modified)
U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

To:	Atty. Dkt. No.	M#	Client Ref.
		0278772	014357

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: November 5, 2003

Page 1 of 1

Applicant: FANG, Fang

Appn. No.: 09/910,483

Filing Date: July 19, 2001

Examiner: Wortman, D. Group Art Unit: 1648

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						
DR						
ER						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
elc	FR	JP10-101699	10/1998	Japan		X		
	GR							
	HR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

elc	IR	Ohtomo, et al., "Humanization of Mouse ONS-M21 Antibody With The Aid of Hybrid Variable Regions," (1995) <i>Molecular Immunology</i> , Vol. 1, No. 6, pp. 407-416.			
	JR	Mateo, et al., "Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.," (1997), <i>Immunotechnology</i> , Vol. 3, pp. 71-81.	Yes		
	KR	Nagahira, et al., "Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor- α (TNF- α)," (1999), <i>Journal of Immunological Methods</i> , Vol. 222, pp. 83-92.	Yes		
	LR	Saldanha, et al., "A single blackmutation in the human kV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," (1999). <i>Molecular Immunology</i> , Vol. 36, pp. 709-719.	Yes		
	MR	Tempest, et al., "Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus," (1995), <i>Int. J. Biol. Macromol.</i> , Vol. 17, No. 1, pp. 37-42.	Yes		
	NR	Carter, et al., "Humanization of an anti-p185(HER2) antibody for human cancer therapy," (1992), <i>Proc. Natl. Acad. Sci.</i> , Vol. 89, pp. 4285-4289.	Yes		
	OR	Presta, et al., "Humanization of an Antibody Directed Against IgE," (1993), <i>Journal of Immunology</i> , Vol. 151, No. 5, pp. 2623-2632.	Yes		

Examiner Emily L. Date Considered: 5/20/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.